Avita Medical – Japanese Patent Granted – Improved Delivery Device
• Patent for improved inhalation delivery device granted by Japan patent office
• Expands intellectual property portfolio with broad application technology for delivery of medications and substances through inhalation pathway
October 2009: Avita Medical Ltd (ASX: AVH) has been notified that the Japan Patent Office has granted the company a Japanese Patent entitled: Improved drug delivery device and methods therefore.
The patent, of broad applicability, relates to the incorporation of feedback and incentive mechanisms into devices for the improved delivery of medications and biologically active substances via the inhalation pathway.
There is a need for improved delivery devices with inhalation being the pathway of choice for many medications and biologically active substances.
Delivery of medication for the treatment and control of respiratory disease, diabetes and hypertension, as well as the delivery of anti-virals, anti-biotics and other biologically active substances represent emerging opportunities for the company’s patented technology.
Avita Medical CEO Dr William F Dolphin said, “The delivery of medication via the inhalation pathway is becoming the technique of choice for a range of medical conditions.”
“Additionally, the delivery of living cells in aerosol suspension via inhalation has tremendous potential for applications in regenerative medical technologies.”
The intellectual property covered under the patent expands and complements Avita’s existing patented technology and follows patents recently granted in the US, China and
Taiwan. The company is continuing to extend its intellectual property position with a widening range of potential products and applications.
- ENDS -
FOR FURTHER INFORMATION PLEASE CONTACT:
William Dolphin
Avita Medical Limited
Tel: +44 (0)1223 341 150
wdolphin@avitamedical.com
Rudi Michelson
(Monsoon Communications)
Tel: +61 (0)3 9620 3333
rudim@monsoon.com.au
ABOUT AVITA MEDICAL LIMITED
Avita Medical Limited (www.avitamedical.com) is a publicly listed, global medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of a wide range of wounds, scars and skin defects. Using proprietary tissueculture/collection technology, the company is able to provide innovative treatment solutions derived from the patient’s own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.
ReCell® is a stand-alone, rapid cell harvesting device that enables surgeons to treat skin defects using the patient’s own cells. The surgeon can prepare a small quantity of cells within 30 minutes on site, replacing the need for skin grafts and obviating the requirement for culturing laboratories. ReCell® has been designed for use in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is gaining acceptance in a number of indications including Vitiligo, a common skin pigmentation disease.
ReCell® is patented, CE marked for the EU and TGA registered in Australia.
Viewed 3264 times by 439 viewers
Related press releases: